<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00525135</url>
  </required_header>
  <id_info>
    <org_study_id>Valproic Acid</org_study_id>
    <nct_id>NCT00525135</nct_id>
  </id_info>
  <brief_title>Valproic Acid (Depakote ER) in Patients With Advanced Thyroid Cancer</brief_title>
  <official_title>A Phase II Trial of Valproic Acid (Depakote ER ®) in Patients With Advanced Thyroid Cancers of Follicular Origin, Who Are Thyroglobulin Positive/RAI Unresponsive</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs such as valproic acid may make thyroid cancers more radioiodine sensitive,
      which will allow for detection of tumor and make further ablation treatment effective.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PURPOSE: This phase II trial is studying how well valproic acid works in treating patients
      with thyroid cancers that do not respond well to other treatments.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    PI left university and study was halted prematurely. No data was analyzed.
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in Thyroglobulin Level</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Number of participants with decreased thyroglobulin level after study treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in Tumor Size</measure>
    <time_frame>Baseline, 16 weeks</time_frame>
    <description>Number of participants with decreased tumor size after study treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Increased Radioactive Iodine Uptake</measure>
    <time_frame>Baseline, 10 weeks</time_frame>
    <description>Number of participants with increased radioiodine uptake on the Thyrogen scan post valproic acid therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Side Effects of Drugs Affecting Quality of Life</measure>
    <time_frame>17 weeks</time_frame>
    <description>Number of participants experiencing &gt; Grade 1 adverse events (including fatigue) attributable to study treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
    <time_frame>up to 10 years post-study treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If a patient exhibits increased radioiodine uptake on the Thyrogen scan post valproic acid therapy, patients will then prepare for ablative treatment and will remain on valproic acid for a total of 16 weeks, until receiving RAI ablation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>If no increased uptake is seen, patients will continue on valproic acid for 6 additional weeks at an increased dosage, totaling an overall treatment time of 16 weeks as well.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valproic Acid</intervention_name>
    <description>OUTLINE: This is a pilot study.
Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.
Quality of life is assessed at the end of every week through a study diary.
Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

        DISEASE CHARACTERISTICS

          -  Diagnosis of advanced/poorly differentiated thyroid cancer of follicular cell origin
             that is radioiodine-unresponsive

          -  Cumulative dose of radioiodine &lt; 800 mCi

          -  No radioiodine uptake on whole body scan within 18 months of enrollment

          -  Inoperable extensive locoregional tumor mass and/or metastatic spread

          -  Failed conventional therapy that included total thyroidectomy AND radioactive iodine I
             131 ablation

          -  Elevated thyroglobulin level (&gt;2ng/ml on thyroid hormone, &gt;10ng/ml off thyroid
             hormone)or Tg-antibody positive

        PATIENT CHARACTERISTICS

        -18 years or older

        Entry lab results:

          -  Hemoglobin &gt; 8.0 gm/dl

          -  Absolute Neutrophil Count &gt; 750 cells/mm3

          -  Platelet count &gt; 75000/mm3

          -  BUN &lt; 1.5 times upper limit of normal (ULN)

          -  Creatinine &lt; 1.5 times ULN

          -  Total protein &gt; 6.4

          -  Total bilirubin should be &lt; 1.5 times ULN.

          -  AST (SGOT), ALT (SGPT), ALKP and amylase &lt; 1.5 times ULN

          -  Amylase &lt; 1.5 times ULN

          -  Albumin &gt; 2.5

          -  Ammonia &lt; 1.5 times ULN

        EXCLUSION CRITERIA:

          -  Not pregnant

          -  No nursing within the past 3 months

          -  No allergy to valproic acid

          -  No coexisting malignancy other than basal cell carcinoma

          -  No hepatic disease or significant dysfunction

          -  Karnofsky score &gt; 80

          -  No pancreatitis

          -  No kidney dysfunction

          -  Fertile patients must use effective contraception
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Electron Kebebew, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCSF Comprehensive Cancer Center</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 28, 2007</study_first_submitted>
  <study_first_submitted_qc>September 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 5, 2007</study_first_posted>
  <results_first_submitted>January 21, 2015</results_first_submitted>
  <results_first_submitted_qc>January 21, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 3, 2015</results_first_posted>
  <last_update_submitted>January 21, 2015</last_update_submitted>
  <last_update_submitted_qc>January 21, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Thyroid Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valproic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Study Intervention</title>
          <description>Patients receive valproic acid daily for 16 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Study Intervention</title>
          <description>Patients receive valproic acid daily for 16 weeks.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Due to a registration error, the PI did not receive notifications to report results until after the data retention period had passed; numeric data are no longer available for analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Due to a registration error, the PI did not receive notifications to report results until after the data retention period had passed; numeric data are no longer available for analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="NA">Due to a registration error, the PI did not receive notifications to report results until after the data retention period had passed; numeric data are no longer available for analysis.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Decrease in Thyroglobulin Level</title>
        <description>Number of participants with decreased thyroglobulin level after study treatment</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Intervention</title>
            <description>Patients receive valproic acid daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Thyroglobulin Level</title>
          <description>Number of participants with decreased thyroglobulin level after study treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Increased Radioactive Iodine Uptake</title>
        <description>Number of participants with increased radioiodine uptake on the Thyrogen scan post valproic acid therapy</description>
        <time_frame>Baseline, 10 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Intervention</title>
            <description>Patients receive valproic acid daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Increased Radioactive Iodine Uptake</title>
          <description>Number of participants with increased radioiodine uptake on the Thyrogen scan post valproic acid therapy</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Side Effects of Drugs Affecting Quality of Life</title>
        <description>Number of participants experiencing &gt; Grade 1 adverse events (including fatigue) attributable to study treatment</description>
        <time_frame>17 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Intervention</title>
            <description>Patients receive valproic acid daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Side Effects of Drugs Affecting Quality of Life</title>
          <description>Number of participants experiencing &gt; Grade 1 adverse events (including fatigue) attributable to study treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Decrease in Tumor Size</title>
        <description>Number of participants with decreased tumor size after study treatment</description>
        <time_frame>Baseline, 16 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Intervention</title>
            <description>Patients receive valproic acid daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Decrease in Tumor Size</title>
          <description>Number of participants with decreased tumor size after study treatment</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Survival</title>
        <time_frame>up to 10 years post-study treatment</time_frame>
        <population>Due to early termination, participants were not followed for survival after the primary outcome timeframe</population>
        <group_list>
          <group group_id="O1">
            <title>Study Intervention</title>
            <description>Patients receive valproic acid daily for 16 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Survival</title>
          <population>Due to early termination, participants were not followed for survival after the primary outcome timeframe</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>17 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Study Intervention</title>
          <description>Patients receive valproic acid daily for 16 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>UCSF PRS Administrator</name_or_title>
      <organization>University of California San Francisco</organization>
      <phone>415-502-3212</phone>
      <email>Elaine.Cooperstein@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

